Indication
Metastatic HER2+ Advanced Breast Cancer
1 clinical trial
1 product
Product
TucatinibClinical trial
A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of Tucatinib (MK-7119) in China Participants With HER2+ Advanced Breast Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2025-01-28